Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 1

The Current Treatment Landscape for R/R CLL

,

Panelists discuss the current standard of care and treatment landscape for patients with chronic lymphocytic leukemia.

Now Viewing
EP. 1: The Current Treatment Landscape for R/R CLL
EP. 2: Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
EP. 3: Key Patient-Specific Factors Guiding Treatment Selection in CLL
EP. 4: Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL
EP. 5: Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL
EP. 6: Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial
EP. 7: Application of Pirtobrutinib in R/R CLL: Expert Perspectives
EP. 8: Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL
EP. 9: Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors
EP. 10: Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL
EP. 11: Treatment Sequencing in Relapsed/Refractory CLL: Key Factors Influencing Decision-Making
EP. 12: Emerging role of doublet triplet therapies in R/R CLL: Expert Perspectives
EP. 13: The Impact of Emerging Resistance Patterns on Treatment Sequencing in R/R CLL
EP. 14: Multidisciplinary Approach to Managing Treatment for Relapsed/Refractory CLL

Video content above is prompted by the following:

  • Please discuss the current treatment landscape for relapse/refractory chronic lymphocytic leukemia.

Related Content:

Insights
Challenges With Avelumab Maintenance in Bladder Cancer and Introduction to ADCs in UC
KEYNOTE-361 Highlights: Challenges and Insights
Multidisciplinary Approach to Managing Treatment for Relapsed/Refractory CLL